Atara Biotherapeutics to Announce First Quarter 2019 Financial Results and Host Conference Call on Thursday, May 9, 2019
May 07, 2019 16:41 ET
|
Atara Biotherapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., May 07, 2019 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments...
Atara Biotherapeutics Presents Off-the-Shelf, Allogeneic CAR T Preclinical Results at the American Association of Cancer Research (AACR) Annual Meeting 2019
April 01, 2019 16:10 ET
|
Atara Biotherapeutics, Inc.
Epstein-Barr virus-specific T cells were engineered to express second-generation CD19 chimeric antigen receptors, eliminated in vitro alloreactivity and inhibited tumor growth in an animal model ...
Atara Biotherapeutics Announces Collaborator Presentation of Positive Phase 1 Clinical Results for a Mesothelin-Targeted CAR T Immunotherapy in Patients with Advanced Mesothelioma
March 31, 2019 11:00 ET
|
Atara Biotherapeutics, Inc.
Memorial Sloan Kettering Cancer Center collaborators presented results that a regionally delivered mesothelin-targeted, autologous CAR T was well-tolerated and showed encouraging anti-tumor activity...
Atara Biotherapeutics to Participate in Upcoming Conferences
March 07, 2019 09:00 ET
|
Atara Biotherapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., March 07, 2019 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel...
Atara Biotherapeutics Announces Presentations Highlighting Next-Generation CAR T Platform and Mesothelin-Targeted CAR T Clinical Results at American Association of Cancer Research (AACR) Annual Meeting 2019
February 27, 2019 17:20 ET
|
Atara Biotherapeutics, Inc.
Atara to present off-the-shelf, allogeneic CAR T proof-of-concept results demonstrating Epstein-Barr virus (EBV)-specific T cells expressing chimeric antigen receptors Memorial Sloan Kettering...
Atara Biotherapeutics Announces Fourth Quarter and Full Year 2018 Financial Results and Recent Operational Progress
February 26, 2019 07:30 ET
|
Atara Biotherapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Feb. 26, 2019 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel...
Atara Biotherapeutics to Participate in the 37th Annual J.P. Morgan Healthcare Conference
January 04, 2019 16:05 ET
|
Atara Biotherapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Jan. 04, 2019 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments...
Atara Biotherapeutics Announces Planned Chief Executive Officer Transition
January 03, 2019 07:40 ET
|
Atara Biotherapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Jan. 03, 2019 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel...
Atara Biotherapeutics Exclusively Licenses Mesothelin-Targeted CAR T Immunotherapy for Solid Tumors
January 03, 2019 07:30 ET
|
Atara Biotherapeutics, Inc.
Initial results from ongoing Phase 1 study for mesothelin-targeted CAR T support activity and safety in patients with advanced solid tumors Atara’s next-generation CAR T collaboration with MSK to...
Atara Biotherapeutics Presents Positive Efficacy and Safety Results for Patients with Epstein-Barr Virus-Associated Leiomyosarcoma (EBV+ LMS)
December 15, 2018 08:00 ET
|
Atara Biotherapeutics, Inc.
Second EBV‑associated solid tumor with encouraging responses to tab-cel®Tab-cel® safety appears consistent with a favorable risk profile and previous observationsResults were presented today in an...